Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment

Dan M Roden; Robert A Harrington; Athena Poppas; Andrea M Russo

doi:10.1161/CIRCULATIONAHA.120.047521

Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment

Circulation. 2020 Jun 16;141(24):e906-e907. doi: 10.1161/CIRCULATIONAHA.120.047521. Epub 2020 Apr 8.

Authors

Dan M Roden¹, Robert A Harrington², Athena Poppas³, Andrea M Russo^{4

5}

Affiliations

¹ Division of Cardiovascular Medicine and Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN (D.M.R.).
² Department of Medicine, Stanford University, CA (R.A.H.).
³ Cardiology Division, Brown University School of Medicine, Providence, RI (A.P.).
⁴ Electrophysiology and Arrhythmia Services, Cooper University Hospital, Camden, NJ (A.M.R.).
⁵ Clinical Cardiac Electrophysiology Fellowship Program, Cooper Medical School of Rowan University, Camden, NJ (A.M.R.).

PMID: 32267732
DOI: 10.1161/CIRCULATIONAHA.120.047521

No abstract available

Keywords: COVID-19; arrhythmias, cardiac; drug effects; drug-related side effects and adverse reactions; severe acute respiratory syndrome coronavirus 2.

Publication types

Review

MeSH terms

Arrhythmias, Cardiac / chemically induced*
Arrhythmias, Cardiac / physiopathology
Azithromycin / adverse effects*
Betacoronavirus*
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy*
Coronavirus Infections / physiopathology
Drug Interactions / physiology
Heart Rate / drug effects
Heart Rate / physiology
Humans
Hydroxychloroquine / adverse effects*
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / physiopathology
SARS-CoV-2
Torsades de Pointes / chemically induced
Torsades de Pointes / physiopathology

Substances

Hydroxychloroquine
Azithromycin